The Anti-CALCRL / CGRPR Reference Antibody (erenumab) is a recombinant monoclonal antibody designed as a reference standard mimicking the therapeutic erenumab (Aimovig®). It targets and blocks the calcitonin gene-related peptide receptor (CGRPR), which is involved in migraine pathophysiology. This reference antibody is primarily used in research, development, and quality control applications, such as bioassays, immunogenicity studies, and pharmacokinetic evaluations. It is not intended for direct therapeutic use in humans. For therapeutic purposes, erenumab is administered as a monthly subcutaneous injection to prevent migraines in adults who have not responded adequately to other preventive treatments, offering a targeted mechanism with a generally favorable safety profile.